TIDMAKR
RNS Number : 4214P
Akers Biosciences, Inc.
05 June 2015
For immediate release
Akers Biosciences, Inc.
Notice of Annual General Meeting
&
Proposed Board Changes
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a medical device company focused on reducing the cost
of healthcare through faster, easier diagnostics, announces that
copies of the Company's annual report for the year ended December
31, 2014, together with a notice convening an Annual General
Meeting ("AGM"), are now available on the Company's website.
The AGM will be held at 10:30 A.M. EST on June 25, 2015 at 11:00
A.M. EST at 50 South 16(th) Street, 57(th) Floor, Philadelphia, PA
19102.
Among the proposals contained in the notice of AGM is the
nomination of former congressman Robert E. "Rob" Andrews as a
Non-executive Director of the Company. Mr. Andrews served as a
Member of the U.S. House of Representatives from 1990 to 2014 as
the Representative for New Jersey's 1st congressional district. In
November 2004, he received more votes than anyone ever elected to
the U.S. House of Representatives from New Jersey.
In the U.S. House of Representatives, Mr. Andrews served on the
Committee on Armed Services, Committee on the Budget, and Committee
on Education and Labor, where he served as chairman of the
Subcommittee on Health, Employment, Labor, and Pensions.
Mr. Andrews was a candidate for the Democratic nomination in the
2008 U.S. Senate election.
Mr. Andrews retired from the House in 2014 to take the position
as Of Counsel at Dilworth Paxson LLP where he also chairs the
Government Affairs Group. Mr. Andrews attended Cornell Law School
from which he graduated magna cum laude in 1982.
"Rob has a deep understanding of the U.S. healthcare system,"
said Raymond Raymond F. Akers, Jr. PhD, Co-founder and Executive
Chairman. "Upon his departure from the House, President Obama
praised his service as "an original author of the Affordable Care
Act...and a vital partner in its passage and implementation." With
more Americans than ever gaining coverage, and Akers Bio producing
reimbursable rapid diagnostic screening tests aimed at major
medical conditions, Rob's perspective and understanding will be
extremely valuable to the Company," continued Dr. Akers. "It will
be an honor to welcome Rob, subject to his election at the AGM, to
the Board of Directors," added Dr. Akers.
Mr. Andrews does not hold any shares in the Company.
This announcement contains all disclosures required to be made
in accordance with Rule 17, Schedule Two (g) of the AIM Rules for
Companies in respect of the proposed appointment of Robert Ernest
Andrews, who is aged 57.
Current Non-executive Director Gavin Moran will not stand for
election at the AGM and will therefore retire from the Board of
Directors with effect from the AGM. The Company is grateful to Mr.
Moran for his contribution as a Non-executive Director.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCMMGGVDKVGKZM
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024
